OCUL LongAnother chance for a clean swing at nearly 2 r/r. Looks like a complex pullback, but pullback it is.
−1.01USD
−80.74 MUSD
58.44 MUSD
135.05 M
About Ocular Therapeutix, Inc.
Sector
CEO
Antony Mattessich
Headquarters
Bedford
Website
Employees (FY)
267
Founded
2006
ISIN
US67576A1007
FIGI
BBG001J1BZV0
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
OCUL - long - upcoming catalystOcular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitation
$OCUL Ocular Therapeutix Inc Long term Target PT 29 and higherNASDAQ:OCUL Ocular Therapeutix Inc
Long term Target PT 29 and higher
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technolo
OCUL is looking attractive OCUL is shaping up for a good risk reward set up.
$3.60 before resistance and well within major downtrend line.
Starter position below $3.
Will add if it falls closer to $2.50, where it has lots of support.
Profit opportunity is 10 - 20%
OCUL good swing opportunity available if price retestsOCUL created a pro gap and if price comes to retest , planning to take a long swing poistion to fill the sep 22 gap .
oculari have no idea what this is but the 50ema is about to coincide with the midpoint of bb, and td89 just happened, so i bet it bounces
$OCUL PT 40 and higherCup and Handle formation
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, an ophthalmic d
OCUL. More Chaos than Order.This is a great example of a chart that makes me realize there is much more to learn. I know there is a way to classify almost every market, but for the life of me I don't know this one.
That makes me all the more motivated to monitor it, however.
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of OCUL is 7.80 USD — it has decreased by 2.38% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Ocular Therapeutix, Inc. stocks are traded under the ticker OCUL.
Ocular Therapeutix, Inc. is going to release the next earnings report on May 10, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for Ocular Therapeutix, Inc. has a max estimate of 24.00 USD and a min estimate of 11.00 USD.
OCUL earnings for the last quarter are −0.01 USD whereas the estimation was −0.29 USD which accounts for 97.89% surprise. Estimated earnings for the next quarter are −0.30 USD. See more details about Ocular Therapeutix, Inc. earnings.
Ocular Therapeutix, Inc. revenue for the last quarter amounts to 15.08 M USD despite the estimated figure of 15.23 M USD. In the next quarter revenue is expected to reach 15.70 M USD.
Yes, you can track Ocular Therapeutix, Inc. financials in yearly and quarterly reports right on TradingView.
Like other stocks, OCUL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Ocular Therapeutix, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 16, 2024, the company has 267.00 employees. See our rating of the largest employees — is Ocular Therapeutix, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Ocular Therapeutix, Inc. EBITDA is −79.40 M USD, and current EBITDA margin is −135.86%. See more stats in Ocular Therapeutix, Inc. financial statements.